Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

A major bottom is in, but there’s a better way to play Canopy Growth stock than buying shares today.
The post Here’s Why It’s Not Too Late to Buy Canopy Growth Stock appeared first on InvestorPlace.

Here’s Why It’s Not Too Late to Buy Canopy Growth Stock

Despite a disastrous 2019, Canopy Growth and its shareholders can be hopeful.

2 Reasons Why Canopy Growth Could Bounce Back in 2020

Roku

Aphria

Invitae

AT&T

Canopy Growth, AT&T, Roku, Aphria and Invitae were our top stock trades for Tuesday. Let's look at the charts.

5 Top Stock Trades for Tuesday: CGC, T, ROKU

Cronos Group

Aurora Cannabis

HEXO Corp

OrganiGram Holdings Inc.

Tilray Brands

One exception to the list of big winners: Aurora Cannabis.

Why Canopy Growth, Cronos Group, and Most Other Top Canadian Pot Stocks Are Jumping Today

Amplify Alternative Harvest ETF

The rebound in marijuana stocks has been one of the more popular 2020 calls among market pundits and news outlets.

3 Marijuana Stocks At Important Time-Price Junctures

Shares of the leading cannabis company proved T.S. Eliot wrong -- April isn't the cruelest month, at least it wasn't for investors last year.

Why Canopy Growth Stock Fell 22% in 2019 After Starting the Year Up 88%

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

GW Pharmaceuticals

Trulieve Cannabis Corp.

Following a disastrous 2019 for the cannabis industry, only nine pot stocks still boast billion-dollar valuations.

The 10 Largest Marijuana Stocks in 2020

Constellation Brands

Following these rules will help minimize the risks of investing in what's thus far been a volatile industry.

3 Resolutions Cannabis Investors Should Make for 2020

One Wall Street analyst seems to think a buyout is likely -- but is it?

Will Constellation Brands Acquire Pot Stock Canopy Growth?

Should You Buy Canopy Growth Stock in 2020?

Cannabis investors will certainly want to forget 2019. In fact, the new year is shaping up to be much better, at least for the top-tier operators like Canopy Growth.

Has the Smoke Finally Cleared for Canopy Growth Stock?

Canopy Growth May Be Ready To Rally

The beer, wine, and spirits distributor saw many of its most important brands strengthen their industry position.

Not Even Canopy Growth Can Be a Buzzkill for Constellation Brands's Q3

Cash is a tough commodity to come by in the cannabis space -- but not for these five pot stocks.

5 Marijuana Stocks With the Most Cash in 2020

The U.S.-listed shares of Canopy Growth Corp. CGC, -3.54% WEED, -2.25% slumped 2.8% in morning trading Wednesday, after Canada-based cannabis company's largest shareholder announced a writedown of its investment that was greater than previous writedowns.

Canopy Growth's stock falls, as stake-holder Constellation Brands writes down more equity losses

After a dismal 2019, the owners of CGC stock are hoping for sunnier days ahead. Will Canopy Growth stock come through for them?

Could the Pain Finally Be Over for Canopy Growth Stock?

2019 was an ugly year for Canopy Growth stock. CGC can rebound in 2020 if it can capitalize on key opportunities.

Two Key Questions for Canopy Growth Stock in 2020

Canopy Growth Corp (TSE: WEED) (NYSE: CGC) announced that it will be working in conjunction with 10 Ontario retail license holders to open new Tokyo Smoke-branded retail cannabis stores across the province.

Canopy Growth Announces 5 More Tokyo Smoke Store Openings In 2020

The Canadian cannabis company will significantly ramp up its retail presence in the province.

Canopy Growth to Open 10 Tokyo Smoke Stores in Ontario

Canopy Growth stock investors are excited about a new CEO at the helm and new Cannabis 2.0 products on the way. CGC stock looks primed for 2020.

Canopy Growth Stock Looks Ready to Gain From Big Catalysts in 2020

There's a lot of activity on the way over the next few weeks for these cannabis stocks.

3 Top Marijuana Stocks to Watch in January

Apple

Investing in the right stocks can be a great way to accelerate your portfolio's growth.

2 Stocks That Could Make You Rich: AAPL & CGC

The financial situation for the beer, wine, and spirits distributor remains complex as it reorients itself.

Will Canopy Growth Weigh Heavily on Constellation Brands in Q3?

There could be a lot more hemp-based CBD products on store shelves this year.

2 Stocks That Could Dominate the Hemp CBD Space in 2020

Canopy’s ramped up spending to get its Cannabis 2.0 products into the hands of consumers along with launching its first hemp-derived CBD product in the U.S., two things InvestorPlace’s Mark Hake believes will continue to hurt the company’s margins.

Did Canopy Growth Stock Just Have a Dead Cat Bounce? 

News for Canopy Growth Stock (CGC)